Navigation Links
PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
Date:6/27/2011

SAN CARLOS, Calif., June 27, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company developing next-generation abuse-resistant prescription drugs, today announced the appointment of Dr. Joseph Stauffer as Chief Medical Officer & VP, Corporate Strategy and Dr. Narinder Banait as VP, Intellectual Property.

Dr. Joseph Stauffer - Chief Medical Officer & VP, Corporate Strategy

Prior to joining PharmacoFore, Dr. Stauffer was Chief Medical Officer and Executive Vice President, Corporate Strategy at DURECT Corporation, a specialty pharmaceutical company focused on the development of pharmaceutical systems to treat chronic debilitating diseases. Prior to joining DURECT, Dr. Stauffer was at Alpharma, Inc. from 2004 to 2009, where his latest position prior to the acquisition of Alpharma by King Pharmaceuticals was as Chief Medical Officer and Senior Vice President of Clinical Research & Medical Affairs.  His responsibilities at Alpharma included oversight of all clinical pharmacology, clinical development, pharmacovigilance, medical affairs, risk management and health outcomes/pharmacoeconomics.  Dr. Stauffer led the development and regulatory efforts that resulted in the approval of EMBEDA®, an abuse-resistant formulation of morphine.  Prior to joining Alpharma, Dr. Stauffer was employed at Abbott Laboratories from 2002 to 2004 as Global Medical Director for Pain Therapeutics.  In that role, he was responsible for Phase I-III trials for Vicodin, Vicoprofen, Dilaudid, as well as novel compounds targeting neuropathic pain.  Prior to Abbott, he worked at the FDA from 2000 to 2002 as a Medical Review Officer in the Analgesic Division of the Center for Drug Evaluation and Research.  While there, he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory and novel pain compounds.  Dr. Stau
'/>"/>

SOURCE PharmacoFore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ,60s cleanup of toxic pollution in Seattle,s ... Lake Washington, ... but sometimes, at least in the case of a little fish called ... study led by researchers at Fred Hutchinson Cancer Research,Center and published online ...
... KV is Now Offering The Complete Line of All Four ... ... the 50 mg ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires ...
... BALTIMORE, May 15 Lentigen Corporation announced today,that ... (NIH) small,business innovation research (SBIR) grants to collaborate ... its proprietary,lentiviral vector (LV) technology to the development ... medical need:, -- Melanoma, with Michael ...
Cached Biology Technology:Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 2Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 3Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 4KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 2KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 3KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 4Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may ... to be more careful. In the wild, a plant whose ... would risk disaster. More than just an insurance policy against ... seed dormancy has long-term advantages too: Plants whose seeds ... to more species, finds in a team of researchers working ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2
... confuse the immune system and thwarting biological defenses. ... neutralize the cancer,s chemical arsenal and boost a patient,s ... time are rarely successful. Now, researchers have developed ... of both an immune-system booster and a chemical to ...
... A new genetic mutation that causes familial amyotrophic lateral ... Lou Gehrig,s Disease, has been identified by a team ... Massachusetts Medical School (UMMS). Mutations to the profilin (PFN1) ... of nerve cell axons, is estimated to account for ...
... times more valuable while improving ecology, according to a ... the online journal PLoS ONE . By ... harmful government subsidies, and putting in place effective management ... year, rather than losing US$13 billion per year. ...
Cached Biology News:Elegant delivery 2Elegant delivery 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
Procollagen type I C-terminal propeptide (human, PICP)...
... Small Molecule Localization in Early Drug ... Get essential drug compound localization ... spectrometry. Protein Discoverys imaging mass spectrometry service ... them with histological images so you can ...
Biology Products: